Zhaoke Ophthalmology’s Low-Dose Atropine Eye Drops Cleared for Evaluation by Australia’s TGA

Bulletin Express

06/15

Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product code: NVK002), designed to slow myopia progression in children and adolescents.

The TGA confirmed on 2 June 2026 that the submission passed its preliminary assessment and will move to full evaluation. Zhaoke’s filing is supported by positive Phase III clinical data, although specific trial metrics were not disclosed in the announcement.

NVK002 employs a proprietary formulation aimed at stabilising low-concentration atropine. According to the company, the preservative-free product carries global intellectual-property protection and delivers a 24-month shelf life.

Management reiterated that successful development or commercialisation is not guaranteed, and cautioned shareholders and potential investors to exercise prudence when dealing in the company’s shares.

The update was released on 15 June 2026 and signed by Chairman Dr. Li Xiaoyi on behalf of the board.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1181639427"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181639427\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181639427?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 12:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181639427","market":"hk","top_or_hot":-1,"title":"Zhaoke Ophthalmology’s Low-Dose Atropine Eye Drops Cleared for Evaluation by Australia’s TGA","media":"Bulletin Express","content":"<p>Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product code: NVK002), designed to slow myopia progression in children and adolescents.</p>\n<p>The TGA confirmed on 2 June 2026 that the submission passed its preliminary assessment and will move to full evaluation. Zhaoke’s filing is supported by positive Phase III clinical data, although specific trial metrics were not disclosed in the announcement.</p>\n<p>NVK002 employs a proprietary formulation aimed at stabilising low-concentration atropine. According to the company, the preservative-free product carries global intellectual-property protection and delivers a 24-month shelf life.</p>\n<p>Management reiterated that successful development or commercialisation is not guaranteed, and cautioned shareholders and potential investors to exercise prudence when dealing in the company’s shares.</p>\n<p>The update was released on 15 June 2026 and signed by Chairman Dr. Li Xiaoyi on behalf of the board.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology’s Low-Dose Atropine Eye Drops Cleared for Evaluation by Australia’s TGA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology’s Low-Dose Atropine Eye Drops Cleared for Evaluation by Australia’s TGA\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-06-15 12:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product code: NVK002), designed to slow myopia progression in children and adolescents.</p>\n<p>The TGA confirmed on 2 June 2026 that the submission passed its preliminary assessment and will move to full evaluation. Zhaoke’s filing is supported by positive Phase III clinical data, although specific trial metrics were not disclosed in the announcement.</p>\n<p>NVK002 employs a proprietary formulation aimed at stabilising low-concentration atropine. According to the company, the preservative-free product carries global intellectual-property protection and delivers a 24-month shelf life.</p>\n<p>Management reiterated that successful development or commercialisation is not guaranteed, and cautioned shareholders and potential investors to exercise prudence when dealing in the company’s shares.</p>\n<p>The update was released on 15 June 2026 and signed by Chairman Dr. Li Xiaoyi on behalf of the board.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06622","symbol_name":"兆科眼科-B","start_time":0,"source_url":"","article_id":"1181639427","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181639427","pubTimestamp":1781497279,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06622":"兆科眼科-B"},"translate_title":"兆科眼科低剂量阿托品滴眼液获澳大利亚TGA审评许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1},"content_text":"Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product code: NVK002), designed to slow myopia progression in children and adolescents.\nThe TGA confirmed on 2 June 2026 that the submission passed its preliminary assessment and will move to full evaluation. Zhaoke’s filing is supported by positive Phase III clinical data, although specific trial metrics were not disclosed in the announcement.\nNVK002 employs a proprietary formulation aimed at stabilising low-concentration atropine. According to the company, the preservative-free product carries global intellectual-property protection and delivers a 24-month shelf life.\nManagement reiterated that successful development or commercialisation is not guaranteed, and cautioned shareholders and potential investors to exercise prudence when dealing in the company’s shares.\nThe update was released on 15 June 2026 and signed by Chairman Dr. Li Xiaoyi on behalf of the board.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}